Clinical trials: Obsessive Compulsive Behavior
Obsessive-Compulsive Disorder
Clinical Outcomes From NOCD Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention
This is a naturalistic, observational study of individuals with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy, augmented with between-session support with text…
- Trial name
- NCT04701372
- Testing
- Exposure and response prevention therapy
- Where
- United States
- Volunteers
- 2,069 people
- Sponsor
- NOCD
Opioid Use Disorder
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
This study will evaluate the efficacy, safety, and tolerability of oral naltrexone used in conjunction with buprenorphine in adults with Opioid Use Disorder transitioning from buprenorphine maintenance prior to the first dose of…
- Trial name
- NCT02696434
- Testing
- Naltrexone, Buprenorphine
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alkermes, Inc.
Obsessive Compulsive Disorder (OCD), Bipolar Disorders
Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
This is a research study looking at whether the way people speak can help predict how well they'll respond to certain mental health treatments.
- Conditions
- Obsessive Compulsive Disorder (OCD), Bipolar Disorders, Major Depressive Disorder, Post-Traumatic Stress Disorder, PTSD
- Trial name
- NCT06823024
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Psyrin Inc.
Methamphetamine Dependence
Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
- Trial name
- NCT00730522
- Testing
- CPP-109 vigabatrin
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Body Dysmorphic Disorders
Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions
Body Dysmorphic Disorder (BDD) is a disabling condition that until recently has been largely ignored. Sufferers of BDD worry excessively and unreasonably about some flaw in their appearance that may be minimal or even…
- Trial name
- BDD (NCT01316627)
- Testing
- Crooked Mirror Externalization Therapy, Mirror Retraining Method
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Westwood Institute for Anxiety Disorders, Inc
Addiction, Opioid Dependence
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.
- Conditions
- Addiction, Opioid Dependence, Opioid Withdrawal
- Trial name
- NCT03813095
- Testing
- APH-1501
- Volunteers
- 32 people
- Sponsor
- Aphios
Alcoholism
GSK1521498 Alcohol Interaction Study
The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together.
- Trial name
- NCT01366573
- Testing
- GSK1521498
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Trichotillomania
Technology Assisted Treatment of Trichotillomania: Open Trial
This open-label feasibility trial evaluates the use of the Keen2 awareness bracelet for adults with trichotillomania (hair-pulling disorder). Participants will use the bracelet for eight weeks.
- Trial name
- NCT07224126
- Testing
- Keen2 Predictive Awareness Bracelet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HabitAware Inc.
Nicotine Addiction, Smoking Cessation
Evaluation of a Smoking Cessation Program for Long-Term Abstinence
This observational study evaluates a structured smoking cessation program delivered via weekly group sessions. The primary objective is to assess participant-reported smoking abstinence following completion of the program and at…
- Trial name
- ESCaPe (NCT06746025)
- Testing
- Quit Center cessation program
- Where
- United States
- Volunteers
- 371 people
- Sponsor
- Quit Center LLC
Opioid-use Disorder, Opioid-related Disorders
An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery
The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine…
- Trial name
- RECOVER® (NCT03604861)
- Testing
- Not applicable - no defined intervention
- Where
- 35 sites in United States
- Volunteers
- 534 people
- Sponsor
- Indivior Inc.
Opiate Addiction, Medication Non-adherence
Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy
This study uses an artificial intelligence platform to automatically confirm medication ingestion. The Health Insurance Portability and Accountability Act (HIPAA)-compliant platform can be downloaded as an 'app' onto any…
- Conditions
- Opiate Addiction, Medication Non-adherence, Addiction, Opioid Dependence
- Trial name
- NCT02243670
- Testing
- AiCure monitoring and intervention
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- AiCure
Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
- Trial name
- NCT00611130
- Testing
- vigabatrin
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Opioid Dependence
An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
This is an open label study in opioid dependent subjects maintained on a stabilized dose of Suboxone tablets or films. The purpose is to assess the safety and tolerability of BEMA Buprenorphine NX administered once daily for 12…
- Trial name
- NCT01666119
- Testing
- BEMA Buprenorphine NX films
- Where
- 10 sites in United States
- Volunteers
- 249 people
- Sponsor
- BioDelivery Sciences International
Substance Dependence
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
- Trial name
- NCT00814957
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opiod Use Disorder
Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®
- Trial name
- NCT05304364
- Testing
- Combination Product: Naltrexone
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Delpor, Inc.
Substance Dependence
GSK618334 Repeat Dose Study
The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.
- Trial name
- NCT01036061
- Testing
- GSK618334 Low Dose, GSK618334 PET subjects, GSK618334 Medium Dose
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Trichotillomania
Feasibility Study for Treating Trichotillomania With Wearable Device and App System
Trichotillomania is characterized by recurrent hair pulling resulting in hair loss causing significant distress and impairment which persists despite repeated attempts to stop.
- Trial name
- NCT04241120
- Testing
- Device and app system designed for participant to self-administer Habit Reversal Training, Reminder bracelet control condition
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HabitAware Inc.
Obsessive-Compulsive Behavior
rTMS Device for Improvement of Obsessive and Compulsive Behaviors
The goal of this investigational study is to evaluate if the treatment using EXOMIND(BTL-699-2) device is able to improve severity of obsessive and compulsive symptoms in adults (aged 22 and older).
- Trial name
- NCT07679750
- Testing
- EXOMIND (BTL-699-2) Active treatment
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Addiction
A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers
The primary objective of this study is to assess the safety and tolerability of a single day dosing and a separate multiple day dosing of 18-MC HCl administered orally, each part of the study having a different set of healthy…
- Trial name
- NCT04292197
- Testing
- 18-MC Compound
- Where
- Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Definium Therapeutics US, Inc.
Addictive Behavior, Alcohol Use Disorder
90-Day Online Substance Use Program
Individuals indicating risky substance use are randomly assigned either to a three-month online intervention on the Workit Health platform or a waitlist/treatment as usual.
- Conditions
- Addictive Behavior, Alcohol Use Disorder, Alcohol Abuse, Drug Abuse
- Trial name
- NCT03069118
- Testing
- Treatment - Workit Health Online Program, Control - Resource List
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Workit Health